Verition Fund Management’s Teva Pharmaceuticals TEVA Stock Holding History

Verition Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.54M	Sell	51,200 -520,300	-91%	-$16.7M	0.01%	1145
2025 Q4	$17.8M	Buy	571,500 +210,900	+58%	+$5.2M	0.07%	219
2025 Q3	$7.28M	Sell	360,600 -12,300	-3%	-$216K	0.03%	774
2025 Q2	$6.25M	Buy	372,900 +152,200	+69%	+$2.46M	0.03%	902
2025 Q1	$3.39M	Buy	220,700 +88,400	+67%	+$1.58M	0.02%	1170
2024 Q4	$2.92M	Sell	132,300 -6,800	-5%	-$124K	0.01%	1288
2024 Q3	$2.51M	Buy	139,100 +2,200	+2%	+$38.5K	0.01%	1280
2024 Q2	$2.22M	Buy	136,900 +86,900	+174%	+$1.34M	0.01%	1202
2024 Q1	$706K	Buy	+50,000	New	+$630K	﹤0.01%	1817
2023 Q2	–	Sell	-25,300	Closed	-$224K	–	2543
2023 Q1	$224K	Hold	25,300	–	–	﹤0.01%	1699
2022 Q4	$231K	Hold	25,300	–	–	﹤0.01%	1659
2022 Q3	$204K	Buy	+25,300	New	+$224K	﹤0.01%	2480

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's TEVA Position: Q1 2026 in Review

Verition Fund Management reduced its Teva Pharmaceuticals (TEVA) stake by 96% in Q1 2026, selling an estimated $9.31M and leaving 13,362 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #1669.

Verition Fund Management first reported a position in TEVA in Q3 2015 and has held it in 24 quarters since. The position peaked at $9.45M in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Verition Fund Management held 13,362 shares of Teva Pharmaceuticals worth $402K as of Q1 2026.
Verition Fund Management sold 289,508 Teva Pharmaceuticals shares in Q1 2026, an estimated $9.31M.
Teva Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1669 holding.
Verition Fund Management first reported a position in Teva Pharmaceuticals in Q3 2015 and has held it in 24 quarters since.
Verition Fund Management's Teva Pharmaceuticals position peaked at $9.45M in Q4 2025.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.